Maze Therapeutics (NASDAQ: MAZE) has been upgraded to a “strong-buy” rating by analysts at Mizuho, according to a report released on Wednesday. This decision reflects growing confidence in the company’s potential as it continues to advance its clinical-stage biotechnology initiatives.
In recent weeks, Maze Therapeutics has attracted attention from several research firms. BTIG Research reiterated a “buy” rating while establishing a price target of $46.00 for the company’s shares. Additionally, Guggenheim increased its price objective from $46.00 to $58.00, maintaining a “buy” rating. This follows a series of assessments, including one from Raymond James Financial, which initiated coverage on the company with an “outperform” rating and a target price of $48.00.
The consensus among analysts regarding Maze Therapeutics is notably optimistic; two research analysts have assigned a “strong buy” rating, while seven have recommended a “buy,” and one has issued a “sell.” According to data compiled by MarketBeat.com, the company holds a consensus rating of “buy” and a target price averaging $54.63.
Insider Trading and Investor Activity
Recent transactions involving company insiders have raised significant interest. Atul Dandekar, an insider at Maze Therapeutics, sold 7,500 shares on January 29 at an average price of $44.27, totaling approximately $332,025.00. Following this transaction, Dandekar retained 10,503 shares, valued at about $464,967.81, marking a 41.66% decrease in his holdings.
Another significant sale occurred on March 10 when Harold Bernstein, the Chief Medical Officer, sold 30,000 shares at an average price of $50.45, resulting in a total transaction value of $1,513,500.00. Over the last quarter, insiders have sold a cumulative total of 230,000 shares, valued at approximately $9,768,292.
Institutional Investments in Maze Therapeutics
Investors have been actively adjusting their positions in Maze Therapeutics. The Royal Bank of Canada increased its stake by 128.3% during the fourth quarter, now holding 646 shares worth around $27,000 after acquiring an additional 363 shares.
Additionally, Ameritas Investment Partners Inc. raised its holdings by 82.6% during the third quarter, bringing its total to 1,632 shares valued at $42,000. Other notable changes include a 138.0% increase in shares held by the California State Teachers Retirement System, which now owns 1,321 shares worth $55,000.
The Police & Firemen’s Retirement System of New Jersey and GF Fund Management CO. LTD. have also increased their positions in the company during the fourth quarter, investing additional resources to capitalize on Maze’s potential growth.
Maze Therapeutics, based in the United States, is a clinical-stage biotechnology company focused on developing novel therapeutics by leveraging insights from human genetics and genomics. The firm utilizes advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to expedite the development of medicines for patients with serious diseases.
As analysts continue to express confidence in Maze Therapeutics, the company’s diverse pipeline and innovative approach to drug discovery position it well for future growth and success in the competitive biotech landscape.
